Modus Therapeutics Holding
0.41 SEK
-2.38 %
Less than 1K followers
MODTX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Modus Therapeutics Holding
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| growth-% | ||||||
| EBITDA | -6.0 | -20.7 | -18.0 | -16.4 | -15.8 | - |
| EBIT | -6.0 | -20.7 | -18.0 | -16.4 | -15.8 | -18.1 |
| Profit before taxes | -6.0 | -20.7 | -18.3 | -17.9 | -15.8 | -18.5 |
| Net income | -6.0 | -20.7 | -18.3 | -17.9 | -15.8 | -18.5 |
| EPS | -0.15 | -0.51 | -0.45 | -0.40 | -0.17 | -0.30 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| EBITDA-% | ||||||
| EBIT-% | ||||||
| ROE | -86.0 % | -131.5 % | 707.3 % | -101.2 % | -740.2 % | -204.4 % |
| ROI | -80.3 % | -97.6 % | -162.6 % | -89.3 % | -324.6 % | -146.2 % |